Paper Details

  1. Home
  2. Paper Details

Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.

Author: Collado-RomachoAntonio Ramon, Corma-GomezAnaïs, Corona-MataDiana, CucurullJosep, De Los SantosIgnacio, GaleraCarlos, García-MartínSofía, Gonzalez-SernaAlejandro, MaciasJuan, MerinoDolores, RealLuis Miguel, Rios-VillegasMaría Jose, RiveroAntonio, SantosMarta, TellezFrancisco

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the sustained viral response (SVR) rates of glecaprevir/pibrentasvir (G/P) in HIV/HCV-coinfected and HCV-monoinfected patients. SVR rates were similar in both groups (95.5% vs 95.1%), highlighting the effectiveness of G/P in HIV/HCV coinfection. However, active drug use was a significant barrier to achieving SVR in the HIV/HCV group.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials. METHODS: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkad278

データ提供：米国国立医学図書館（NLM）

Glecaprevir/Pibrentasvir: A Ray of Hope in the Desert of HIV/HCV Coinfection

This research investigates the effectiveness of glecaprevir/pibrentasvir (G/P), a combination therapy for hepatitis C virus (HCV) infection, in patients coinfected with HIV. The authors compared the treatment outcomes of HIV/HCV coinfected patients with those who were HCV-monoinfected.

G/P: A Potential Oasis in the Desert

The study found that G/P was highly effective and well-tolerated in both HIV/HCV coinfected and HCV-monoinfected patients, with similar rates of sustained viral response. It's like finding a refreshing oasis in the vast and challenging desert of HIV/HCV coinfection.

HIV/HCV Coinfection: A Complex Desert

HIV/HCV coinfection presents unique challenges for treatment. This research offers a beacon of hope, suggesting that G/P could be a valuable tool for managing this complex condition.

Dr.Camel's Conclusion

The effectiveness of G/P in HIV/HCV coinfection is a promising development. It's like finding a source of water in a desolate desert, offering a potential cure for a challenging medical condition. This research highlights the importance of continued research and development of new antiviral therapies to combat the global burden of HIV/HCV coinfection.
Date :
  1. Date Completed 2023-10-04
  2. Date Revised 2023-10-11
Further Info :

Pubmed ID

37671831

DOI: Digital Object Identifier

10.1093/jac/dkad278

Related Literature

Article Analysis
・Side Effects of glecaprevir and pibrentasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.